Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in Advanced Non-small Cell Lung Cancer
NCT06907615Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Jun 2025
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of HLX43 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Henlius. Primary endpoint: Objective Response Rate at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
HLX43
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06907615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907615.